ONO-7428-01: A phase I, open-label, dose escalation study to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors

Ono Pharmaceutical Co.,LTD0 个研究点目标入组 60 人开始时间: 2025年4月21日最近更新: 2025年6月2日

试验速览

暂无简介。

•Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors.
•[Backfill cohort only] Participants with histologically or cytologically confirmed Stage IIIB, IIIC, IV, or recurrent NSCLC according to UICC-TNM classification .
•Participants who are refractory or intolerant to standard therapy.
•Participants with a tumor type for which anti-PD-(L)1 antibodies have been approved and who have previously treated with anti-PD-(L)1 antibody containing regimen.
•Participants with Eastern Cooperative Oncology Group Performance Status 0 or
•Participants with tumor tissue samples available for biomarker testing.

•Participants with a complication or history of severe hypersensitivity to any other antibody drugs.
•Participants with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease
•Participants with severe peritoneal dissemination.
•Participants with pericardial fluid, pleural effusion, or ascites requiring treatment.
•Participants with uncontrolled tumor-related pain.
•Participants with active or history of interstitial lung disease or pulmonary fibrosis.

Tolerability, safety

未报告次要终点

发起方